1. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta- analysis of controlled clinical trials 
Daniel R. Morales, MBChB, Brian J. Lipworth, MD, Bruce Guthrie, PhD, Cathy Jackson, MD, Peter T. Donnan, PhD, Virginia H. Santiago, MBBM 
Journal of Allergy and Clinical Immunology 
Volume 134, Issue 1, Pages e10 (July 2014)
DOI: /j.jaci
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1 PRISMA flow diagram for study selection.
Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
Respiratory symptoms after acute selective NSAID or COX-2 inhibitor exposure in patients with AERD. M-H, Mantel-Haenszel.
Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Fig 3
Decrease in FEV1 of 20% or greater after acute selective NSAID or COX-2 exposure in patients with AERD. M-H, Mantel-Haenszel.
Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5. Fig 4
Nasal symptoms after acute selective NSAID or COX-2 exposure in patients with AERD. M-H, Mantel-Haenszel.
Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6. Fig E1
Respiratory symptoms after acute selective NSAIDs or COX-2 inhibitors in patients with AERD according to leukotriene antagonist exposure status. M-H, Mantel-Haenszel.
Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7. Fig E2
Decreases in FEV1 of 20% or greater after acute selective NSAIDs or COX-2 inhibitors in patients with AERD according to leukotriene antagonist exposure status. M-H, Mantel-Haenszel.
Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

8. Fig E3
Nasal symptoms after acute selective NSAIDs or COX-2 inhibitors in patients with AERD according to leukotriene antagonist exposure status. M-H, Mantel-Haenszel.
Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

9. Fig E4
Respiratory symptoms after acute selective NSAIDs or COX-2 inhibitors in patients with AERD according to random allocation. M-H, Mantel-Haenszel.
Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

10. Fig E5
Decreases in FEV1 of 20% or greater after acute selective NSAIDs or COX-2 inhibitors in patients with AERD according to random allocation. M-H, Mantel-Haenszel.
Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

11. Fig E6
Nasal symptoms after acute selective NSAIDs or COX-2 inhibitors in patients with AERD according to random allocation. M-H, Mantel-Haenszel.
Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

12. Fig E7 Risk of bias table for included studies.
Journal of Allergy and Clinical Immunology  , e10DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions